Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

3 U.S. Children with COVID-19 Have Rare Inflammatory Syndrome

Julie Steenhuysen  |  April 29, 2020

CHICAGO (Reuters)—Three U.S. children infected with the coronavirus are being treated for a rare inflammatory syndrome that appears similar to one that has raised concerns by doctors in Britain, Italy and Spain, a specialist treating the patients told Reuters.

All three—who range in age from 6 months to 8 years—have undergone treatment at Columbia University Medical Center, New York, and all had fever and inflammation of the heart and the gut, suggestive of Kawasaki disease.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Right now, we’re at the very beginning of trying to understand what that represents,” Columbia’s Mark Gorelik, MD, tells Reuters.

Dr. Gorelik, a pediatric rheumatologist and immunologist, says he was called in to consult on the cases to evaluate whether the children have Kawasaki disease, an illness thought to be linked to infection that in severe cases causes inflammation of the arteries of the heart.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Italian and British medical experts are investigating a possible link between the coronavirus pandemic and clusters of severe inflammatory disease among infants arriving in hospitals with high fevers and swollen arteries.

The syndrome has been largely undetected in the United States, according to the American Academy of Pediatrics.

Dr. Gorelik says he believes the cases are likely not Kawasaki disease, but a similar process that shares an underlying mechanism with Kawasaki, which is thought to be triggered by an infectious agent that sparks an immune response.

“This has very similar features,” he says.

The three New York cases follow a report at Stanford University, California, in which a 6-month-old was admitted to the hospital with Kawasaki disease and was later diagnosed with COVID-19.

“When the baby came back positive, it was a bit of a surprise,” says Roshni Mathew, MD, a pediatric infectious disease specialist at Stanford’s Lucile Packard Children’s Hospital.

Dr. Mathew, who wrote up the case in the journal Hospital Pediatrics, says the cause of Kawasaki disease is not known, but several pathogens have been suggested as a possible trigger, including some human coronaviruses.1

Until now, children have largely escaped some of the more serious complications of COVID-19, which has taken its greatest toll on older adults and those with chronic conditions.

Dr. Gorelik says it’s possible that in some children, the disease has two phases—the initial infection and a secondary immune response that kicks in some weeks later.

“It seems a week to two weeks later, you may have the immune system responding in a very disorganized way,” he says.

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsPediatric Conditions Tagged with:coronavirusCOVID-19heartKawasaki diseasePediatric

Related Articles
    MIA Studio / shutterstock.com

    Kawasaki Guideline Urges Treatment Intensification for Some Patients

    December 16, 2021

    A soon-to-be published guideline from the ACR and the Vasculitis Foundation on Kawasaki disease underscores the importance of early diagnosis and intensified treatment for people with this serious condition.1 Intravenous immunoglobulin (IVIG) remains the treatment mainstay, and prompt, aggressive treatment may be able to reduce the risk of serious complications in some patients. The guideline…

    Dr. Kawasaki

    Tomisaku Kawasaki, Pediatrician Who Discovered Disease That Bears His Name, Dies at 95

    June 18, 2020

    Japanese pediatrician Tomisaku Kawasaki, MD, who identified an inflammatory syndrome that affects children, died on June 5 in Tokyo. He was 95. Tenacity & Attention to Detail Born Feb. 7, 1925, in Tokyo, Dr. Kawasaki graduated from medical school at what is now Chiba University in Chiba, Japan, in 1948 and worked as staff pediatrician…

    Exploring Kawasaki Disease

    April 2, 2014

    New epidemiologic data, clinical studies have shed light on diagnosis, treatments, patient outcomes for this childhood disease, but etiology is still unknown

    Thinking Big, Thinking Small

    June 17, 2019

    I would like to tell you a story. Two, actually. I am just returning from the 19th International Vasculitis and ANCA Workshop, which is always a fascinating meeting. In its inception, it was a workshop, in the true sense of the word. Now, we discuss anti-neutrophil cytoplasmic antibody (ANCA) testing as casually as we discuss…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences